{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T16:34:24Z","timestamp":1776875664077,"version":"3.51.2"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1097\/pas.0000000000000488","type":"journal-article","created":{"date-parts":[[2015,9,10]],"date-time":"2015-09-10T23:07:46Z","timestamp":1441926466000},"page":"1363-1369","source":"Crossref","is-referenced-by-count":21,"title":["Dasatinib-related Follicular Hyperplasia"],"prefix":"10.1097","volume":"39","author":[{"given":"Michael G.","family":"Ozawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark D.","family":"Ewalt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dita","family":"Gratzinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-8-20210131","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3324\/haematol.2009.011452","article-title":". Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib.","volume":"95","author":"Shah","year":"2010","journal-title":"Haematologica"},{"key":"R2-8-20210131","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":". Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"},{"key":"R3-8-20210131","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":". Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"R4-8-20210131","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.3109\/10428194.2012.695779","article-title":". Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia.","volume":"53","author":"Steegmann","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"R5-8-20210131","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1182\/blood-2013-07-513879","article-title":". Reversible lymph node follicular hyperplasia associated with dasatinib treatment of chronic myeloid leukemia in chronic phase.","volume":"122","author":"Roux","year":"2013","journal-title":"Blood"},{"issue":"suppl 1","key":"R6-8-20210131","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1038\/modpathol.2012.176","article-title":"Benign lymphadenopathies.","volume":"26","author":"Weiss","year":"2013","journal-title":"Mod Pathol"},{"key":"R7-8-20210131","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.hoc.2009.04.005","article-title":"Atypical lymphoid hyperplasia mimicking lymphoma.","volume":"23","author":"Good","year":"2009","journal-title":"Hematol Oncol Clin North Am"},{"key":"R8-8-20210131","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1097\/PAS.0b013e318264e223","article-title":". TdT T-lymphoblastic populations are increased in Castleman disease, in Castleman disease in association with follicular dendritic cell tumors, and in angioimmunoblastic T-cell lymphoma.","volume":"35","author":"Ohgami","year":"2012","journal-title":"Am J Surg Pathol"},{"key":"R9-8-20210131","first-page":"19","article-title":"Lymphocyten und ihre funktionsformenMorphologie, organisation und immunologische bedeutung.","volume":"69","author":"Lennert","year":"1975","journal-title":"Verh Anat Ges"},{"key":"R10-8-20210131","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000063057","article-title":". Progressive transformation of germinal centers. Report of 2 cases and review of the literature.","volume":"108","author":"Verma","year":"2002","journal-title":"Acta Haematol"},{"key":"R11-8-20210131","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/PAP.0b013e3181a9d4d3","article-title":"Castleman disease: an update on classification and the spectrum of associated lesions.","volume":"16","author":"Cronin","year":"2009","journal-title":"Adv Anat Pathol"},{"key":"R12-8-20210131","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/leu.2014.12","article-title":". B-cell receptor pathway inhibitors affect CD20 levels and impair antitumor activity of anti-CD20 monoclonal antibodies.","volume":"28","author":"Bojarczuk","year":"2014","journal-title":"Leukemia"},{"key":"R13-8-20210131","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1158\/1078-0432.CCR-10-2572","article-title":". Dasatinib plus nutilin-3 shows synergistic antileukemic activity in both p53 wild-type and p53 mutated B chronic lymphocytic leukemias by inhibiting the Akt pathway.","volume":"17","author":"Zauli","year":"2011","journal-title":"Clin Cancer Res"},{"key":"R14-8-20210131","doi-asserted-by":"crossref","first-page":"4726","DOI":"10.1182\/blood-2010-12-323238","article-title":". Age-related EBV-associated lymphoproliferative disorders in the Western population: a spectrum of reactive lymphoid hyperplasia and lymphoma.","volume":"117","author":"Dojcinov","year":"2011","journal-title":"Blood"},{"key":"R15-8-20210131","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/j.1365-2362.2009.02206.x","article-title":". Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily.","volume":"39","author":"Sillaber","year":"2009","journal-title":"Eur J Clin Invest"},{"key":"R16-8-20210131","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1309\/AJCPQYYE04AVGVYI","article-title":". Early posttransplant lymphoproliferative disease: clinicopathologic features and correlation with mTOR signaling pathway activation.","volume":"138","author":"Nelson","year":"2012","journal-title":"Am J Clin Pathol"},{"key":"R17-8-20210131","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1002\/cncr.22936","article-title":". The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in Philadelphia chromosome-negative cells.","volume":"110","author":"Deininger","year":"2007","journal-title":"Cancer"},{"key":"R18-8-20210131","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s00277-013-1816-z","article-title":". Clonal chromosomal abnormalities in Philadelphia-negative cells in chronic myeloid leukemia patients treated with nilotinib used in first-line therapy.","volume":"92","author":"Wang","year":"2013","journal-title":"Ann Hematol"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000000488","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T04:45:23Z","timestamp":1620967523000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000478-201510000-00008"}},"subtitle":["An Underrecognized Entity With Characteristic Morphology"],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":18,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000000488","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]}}}